The Prevalence of Human Papillomavirus Type 58 in Chinese Patients with Cervical Carcinoma and its Influence on Survival

Clinical Oncology

Volumn 21, Issue 10, 2009, Pages 768-774

  Shah, Walayat ^a   Hongwei, Chen ^a   Jin, Zheng ^a   Lifang, Dong ^a   Jun, Yu ^b   Yili, Wang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cervical carcinoma; chemoradiotherapy; human papillomavirus; prevalence; radiotherapy; survival

Indexed keywords

CISPLATIN; FLUOROURACIL; VINCRISTINE;

ADULT; AGED; ARTICLE; CHINA; CHINESE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DNA EXTRACTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; INFECTION RATE; MAJOR CLINICAL STUDY; MICROWAVE THERAPY; MIXED INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SURVIVAL RATE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CHINA; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 70449517256     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.09.003     Document Type: Article

References (42)

1. Boffetta P., and Parkin D.M. Cancer in developing countries. CA Cancer J Clin 44 (1994) 81-90
2. Montana G.S., Fowler W.C., Varia M.A., Walton L.A., Mack Y., and Shemanski L. Carcinoma of the cervix, stage III. Results of radiation therapy. Cancer 57 (1986) 148-154
3. Perez C.A., Camel H.M., Kuske R.R., et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience. Gynecol Oncol 23 (1986) 127-140
4. Coia L., Won M., Lanciano R., Marcial V.A., Martz K., and Hanks G. The patterns of care outcome study for cancer of the uterine cervix. Results of the second national practice survey. Cancer 66 (1990) 2451-2456
5. Goonatillake S., Khong R., and Hoskin P. Chemoradiation in gynaecological cancer. Clin Oncol 21 (2009) 566-572
6. Walboomers J.M.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cancer worldwide. J Pathol 189 (1999) 12-19
7. King L.A., Tase T., Twiggs L.B., et al. Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix. Cancer 63 (1989) 897-900
8. Kenter G.G., Cornelisse C.J., Jiwa N.M., et al. Human papillomavirus type 16 in tumour tissue of low-stage squamous carcinoma of the uterine cervix in relation to ploidy grade and prognosis. Cancer 71 (1993) 397-401
9. Kristensen G.B., Karlsen F., Jenkins A., Kaern J., Abeler V.M., and Trope C.G. Human papillomavirus has no prognostic significance in cervical carcinoma. Eur J Cancer 32A (1996) 1349-1353
10. De Britton R.C., Hildesheim A., De Lao S.L., Brinton L.A., Sathya P., and Reeves W.C. Human papillomaviruses and other influences on survival from cervical cancer in Panama. Obstet Gynecol 81 (1993) 19-24
11. Riou G., Favre M., Jeannel D., Bourhis J., Le D.V., and Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 335 (1990) 1171-1174
12. Ji H.X., Syrjänen S., Klemi P., Chang F., Tosi P., and Syrjänen K. Prognostic significance of nuclear DNA content and human papillomavirus (HPV) type in invasive cervical cancer. Polymerase chain reaction (PCR) and flow cytometric analysis. Int J Gynecol Cancer 1 (1991) 59-67
13. Higgins G.D., Davy M., Roder D., Uzelin D.M., Phillips G.E., and Burrell C.J. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 338 (1991) 910-913
14. Nakagawa S., Yoshikawa H., Onda T., Kawana T., Iwamoto A., and Taketani Y. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 78 (1996) 1935-1941
15. Lombard I., Vincent-Salomon A., Validire P., et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 16 (1998) 2613-2619
16. Shi S.-R., Cote R.J., Wu L., et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem 50 (2002) 1005-1011
17. Hu L., Guo M., He Z., Thornton J., McDaniel L.S., and Hughson M.D. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 18 (2005) 267-273
18. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
19. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
20. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358 (2001) 781-786
21. Munoz N., Bosch F.X., Castellsague X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
22. Cooper K., Herrington C.S., Lo E.S., Evans M.F., and McGee J.O. Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma. J Clin Pathol 45 (1992) 382-384
23. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 (2003) 63-73
24. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
25. Bosch F.X., Manos M.M., Muñoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study of Cervical Cancer (IBSCC) Study group. J Natl Cancer Inst 87 (1995) 796-802
26. Herrero R., Hildesheim A., Bratti C., et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92 (2000) 464-474
27. Park H.K., Kim Y.N., Jeong D.H., Lee K.B., Sung M.S., and Kim K.T. Human papillomavirus (HPV) in lymphatic fluid of patients with cervical cancer. Korean J Gynecol Oncol 16 (2005) 61-69
28. Maria del Refugio G.L., Iván R.L., Nina V.G., and Marylin P.S. High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J Clin Virol 29 (2004) 202-205
29. Nishiwaki M., Yamamoto T., Tone S., et al. Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol 46 (2008) 1161-1168
30. Huang S., Afonina I., Miller B.A., and Beckmann A.M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 70 (1997) 408-411
31. Lai H.C., Sun C.A., Yu M.H., Chen H.J., Liu H.S., and Chu T.Y. Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. Int J Cancer (Pred Oncol) 84 (1999) 553-557
32. Lin M., Yang L.Y., Li L.J., Wu J.R., Peng Y.P., and Luo Z.Y. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol 48 (2008) 189-194
33. Trottier H., Mahmud S., Costa M.C., et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 15 (2006) 1274-1280
34. Liaw K.L., Hildesheim A., Burk R.D., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 (2001) 8-15
35. Rousseau M.C., Pereira J.S., Prado J.C., Villa L.L., Rohan T.E., and Franco E.L. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184 (2001) 1508-1517
36. Mendez F., Munoz N., Posso H., et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 192 (2005) 1158-1165
37. Jarrell M.A., and Howard P. Squamous cell carcinoma of the cervix: HPV 16 and DNA ploidy as predictors of survival. Gynecol Oncol 36 (1992) 361-366
38. van Bommel P.F., van den Brule A.J., Helmerhorst T.J., et al. HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer. Gynecol Oncol 48 (1993) 333-337
39. Vernon S.D., Unger E.R., Miller D.L., Lee D.R., and Reeves W.C. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int J Cancer 74 (1997) 50-56
40. Kalantari M., Karlsen F., Kristensen G., Holm R., Hagmar B., and Johansson B. Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 17 (1998) 146-153
41. Liaw K.L., Hsing A.W., Schiffman M.H., et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women. Int J Cancer 73 (1997) 775-776
42. Bachtiary B., Obermair A., Dreier B., et al. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int J Cancer 102 (2002) 237-243